SILO
NASD Silo Pharma Inc$1.49 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.49, and at the day’s high of $1.49
- YTD change
- -70.78%
- vs 20-day SMA
- -9.95%
- vs 200-day SMA
- -69.51%
Price ranges
Price & Performance
+1.06 (+245.79%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.7% away from all-time highs of $442.50
- SILO is down 71% since the beginning of the year
- SILO is down 82% over the past 12 months
- SILO is down 29% over the past 1 month
- 2% of all SILO investors are betting against SILO
SILO reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +137.2%.
- Previous minute
- +$0.00
- Last hour
- -$0.02
- Last 5 days
- +2.19%
- vs 8-day SMA
- +1.29%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.
Competitor comparison
| Ticker | Company | Price | Change |
|---|---|---|---|
| HESAY | Hermes International Societe en commandite par actions Unsponsored ADR | $142.52 | -1.29% |
| ONON | On Holding AG Class A | $35.35 | +0.74% |
| ATZAF | Aritzia, Inc. | $103.49 | +0.65% |
| BSDGY | Bosideng International Holdings Limited Unsponsored ADR | $27.50 | +13.40% |
| FIGS | FIGS, Inc. Class A | $17.74 | +12.42% |
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.